The glycolytic enzymes hexokinase II and glyceraldehyde 3-phosphate dehydrogenase (Gapdh) were significantly reduced after HBO treatment, opposing the tumor specific metabolic glycolytic phenotype. The gene discussed is GAPDH; the disease is neoplasm.